The biotechnology company Amgen was founded in 1980 as AMGen. With approximately 20,000 employees, Amgen is one of the world's largest biotechnology companies with annual sales of approximately $ 24 billion in 2018.
P/E ratio for Amgen (AMGN)
P/E ratio as of December 2023 (TTM): 19.1
According to Amgen's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 19.0558. At the end of 2022 the company had a P/E ratio of 21.6.
P/E ratio history for Amgen from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 21.6 | -0.7% |
| 2021 | 21.7 | 17.02% |
| 2020 | 18.6 | -0.31% |
| 2019 | 18.6 | 21.35% |
| 2018 | 15.3 | -76.8% |
| 2017 | 66.1 | 366.71% |
| 2016 | 14.2 | -20.05% |
| 2015 | 17.7 | -24.46% |
| 2014 | 23.5 | 38.6% |
| 2013 | 16.9 | 9.96% |
| 2012 | 15.4 | -2.67% |
| 2011 | 15.8 | 38.85% |
| 2010 | 11.4 | -8.79% |
| 2009 | 12.5 | -18.26% |
| 2008 | 15.3 | -7.89% |
| 2007 | 16.6 | -39.3% |
| 2006 | 27.3 | 2.56% |
| 2005 | 26.6 | -22.75% |
| 2004 | 34.5 | -2.88% |
| 2003 | 35.5 | -167.58% |
| 2002 | -52.5 | -198.68% |
| 2001 | 53.2 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 11.0 | -42.38% | 🇺🇸 USA |
 Pfizer PFE | 16.4 | -14.03% | 🇺🇸 USA |
 AbbVie ABBV | 38.7 | 103.01% | 🇺🇸 USA |
 Eli Lilly LLY | 109 | 471.27% | 🇺🇸 USA |
 Biogen BIIB | 12.7 | -33.46% | 🇺🇸 USA |
 Gilead Sciences GILD | 17.4 | -8.43% | 🇺🇸 USA |
 Illumina ILMN | -3.83 | -120.11% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 12.4 | -34.73% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 10.3 | -46.05% | 🇬🇧 UK |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.